TY - JOUR
T1 - Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines
AU - Rizza, Pietro
AU - Barone, Ines
AU - Zito, Domenico
AU - Giordano, Francesca
AU - Lanzino, Marilena
AU - De Amicis, Francesca
AU - Mauro, Loredana
AU - Sisci, Diego
AU - Catalano, Stefania
AU - Wright, Karin Dahlman
AU - Gustafsson, Jan ake
AU - Andò, Sebastiano
N1 - Funding Information:
This work was supported by Progetti di Ricerca di Interesse Nazionale (PRIN), Ministero Istruzione Universita` e Ricerca (MIUR) (grant number 20085Y7XT5); and Associazione Italiana Ricerca sul Cancro (AIRC) (grant number 11595). ’Futuro in ricerca’ RBFR12FI27 to IB. Lilli Funaro Fondation to DZ.
PY - 2014/2/19
Y1 - 2014/2/19
N2 - Introduction: The two isoforms of estrogen receptor (ER) alpha and beta play opposite roles in regulating proliferation and differentiation of breast cancers, with ER-alpha mediating mitogenic effects and ER-beta acting as a tumor suppressor. Emerging data have reported that androgen receptor (AR) activation inhibits ER-positive breast cancer progression mainly by antagonizing ER-alpha signaling. However, to date no studies have specifically evaluated a potential involvement of ER-beta in the inhibitory effects of androgens.Methods: ER-beta expression was examined in human breast cancer cell lines using real-time PCR, Western blotting and small interfering RNA (siRNA) assays. Mutagenesis studies, electromobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) analysis were performed to assess the effects of mibolerone/AR on ER-beta promoter activity and binding.Results: In this study, we demonstrate that mibolerone, a synthetic androgen ligand, up-regulates ER-beta mRNA and protein levels in ER-positive breast cancer cells. Transient transfection experiments, using a vector containing the human ER-beta promoter region, show that mibolerone increases basal ER-beta promoter activity. Site-directed mutagenesis and deletion analysis reveal that an androgen response element (ARE), TGTTCT motif located at positions -383 and -377, is critical for mibolerone-induced ER-beta up-regulation in breast cancer cells. This occurs through an increased recruitment of AR to the ARE site within the ER-beta promoter region, along with an enhanced occupancy of RNA polymerase II. Finally, silencing of ER-beta gene expression by RNA interference is able to partially reverse the effects of mibolerone on cell proliferation, p21 and cyclin D1 expression.Conclusions: Collectively, these data provide evidence for a novel mechanism by which activated AR, through an up-regulation of ER-beta gene expression, inhibits breast cancer cell growth.
AB - Introduction: The two isoforms of estrogen receptor (ER) alpha and beta play opposite roles in regulating proliferation and differentiation of breast cancers, with ER-alpha mediating mitogenic effects and ER-beta acting as a tumor suppressor. Emerging data have reported that androgen receptor (AR) activation inhibits ER-positive breast cancer progression mainly by antagonizing ER-alpha signaling. However, to date no studies have specifically evaluated a potential involvement of ER-beta in the inhibitory effects of androgens.Methods: ER-beta expression was examined in human breast cancer cell lines using real-time PCR, Western blotting and small interfering RNA (siRNA) assays. Mutagenesis studies, electromobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) analysis were performed to assess the effects of mibolerone/AR on ER-beta promoter activity and binding.Results: In this study, we demonstrate that mibolerone, a synthetic androgen ligand, up-regulates ER-beta mRNA and protein levels in ER-positive breast cancer cells. Transient transfection experiments, using a vector containing the human ER-beta promoter region, show that mibolerone increases basal ER-beta promoter activity. Site-directed mutagenesis and deletion analysis reveal that an androgen response element (ARE), TGTTCT motif located at positions -383 and -377, is critical for mibolerone-induced ER-beta up-regulation in breast cancer cells. This occurs through an increased recruitment of AR to the ARE site within the ER-beta promoter region, along with an enhanced occupancy of RNA polymerase II. Finally, silencing of ER-beta gene expression by RNA interference is able to partially reverse the effects of mibolerone on cell proliferation, p21 and cyclin D1 expression.Conclusions: Collectively, these data provide evidence for a novel mechanism by which activated AR, through an up-regulation of ER-beta gene expression, inhibits breast cancer cell growth.
UR - http://www.scopus.com/inward/record.url?scp=84896696950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896696950&partnerID=8YFLogxK
U2 - 10.1186/bcr3619
DO - 10.1186/bcr3619
M3 - Article
C2 - 24552459
AN - SCOPUS:84896696950
SN - 1465-5411
VL - 16
JO - Breast Cancer Research
JF - Breast Cancer Research
IS - 1
M1 - R21
ER -